Search clinical trials for: MTR105

Total 73 results

Meditor Pharmaceuticals Ltd.

Withdrawn

Pharmacokinetics and Pharmacodynamics of MTR105 in Hypotensive Cardiac Surgery Patients

Hypotension | Cardiopulmonary Bypass

United States
Wolfson Medical Center
Meditor Pharmaceuticals Ltd.

Unknown

Pharmacokinetic and Pharmacodynamic Effects of MTR107 in End-Stage Renal Disease (ESRD) Patients

End Stage Renal Disease | Hypotension | Intra Dialytic Hypotension

Israel
National Cancer Institute (NCI)

Terminated

TRC105 for Recurrent Glioblastoma

Glioblastoma Multiforme

United States
Aurigene Discovery Technologies Limited

Recruiting

First in Human, Dose Escalation, Dose Expansion Study of AUR105 (SURYA-1)

Hodgkin Lymphoma | Solid Tumor, Adult | Non-hodgkin Lymphoma

India
National Cancer Institute (NCI)

Completed

TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma

Urothelial Carcinoma | Ureteral Neoplasms | Ureter Cancer | Cancer of the Ureter | Neoplasm, Ureteral

United States
Galapagos NV

Terminated

A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis (GECKO)

Atopic Dermatitis

United States
Oncoethix GmbH

Completed

A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)

Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Castrate-resistant Prostate Cancer | CRPC | NUT Midline Carcinoma | Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation
Tarapeutics Science Inc.

Recruiting

TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors

Advanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory

China
Mthera Pharma Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's Disease

Parkinson's Disease
Alan Richardson
Quotient Clinical

Terminated

First in Human Single Ascending Dose Study of MOR107

Safety

United Kingdom
National Cancer Institute (NCI)

Completed

A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)

Prostate Cancer | Metastatic Castrate Resistant Prostate Cancer

United States
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd

Not yet recruiting

Phase I Clinical Study of BR105 Injection (BR105-I)

Advanced Malignancies

China
Tracon Pharmaceuticals Inc.

Completed

Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Recurrent Ovarian Cancer

United States
Galapagos NV

Terminated

A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a Study Drug Called MOR106, in Healthy Subjects and in Patients With Moderate to Severe Atopic Dermatitis

Healthy | Atopic Dermatitis

Spain, Germany, Ukraine, United Kingdom
MorphoSys AG

Completed

Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis

Multiple Sclerosis

Germany, Poland, United Kingdom
Galapagos NV
MorphoSys AG

Completed

First in Human of Single and Multiple Doses of MOR106

Healthy | Dermatitis, Atopic

Belgium, Hungary, Moldova, Republic of, Romania
Sangamo Therapeutics

Active, not recruiting

Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients (STEADFAST)

End Stage Renal Disease | Kidney Transplant Rejection

Belgium, Netherlands, United Kingdom
National Cancer Institute (NCI)

Completed

TRC105 for Liver Cancer That Has Not Responded to Sorafenib

Carcinoma, Hepatocellular | Hepatocellular Carcinoma | Hepatocellular Cancer

United States
University of Alabama at Birmingham
Tracon Pharmaceuticals Inc.

Completed

A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer

Lung Cancer

United States
Tracon Pharmaceuticals Inc.

Completed

Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC

Carcinoma, Non-Small-Cell Lung

United States
Meenakshi Ammal Dental College and Hospital

Completed

microRNA 155 Levels and Periodontal Microflora (Bacteria and Virus) in Preeclampsia.

Chronic Periodontitis | Preeclampsia

India
Tracon Pharmaceuticals Inc.

Completed

A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma

Advanced Soft Tissue Sarcoma

United States
Mthera Pharma Co., Ltd.
Amarex Clinical Research

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Profile of MT101-5 in Healthy Volunteers

Parkinson's Disease

United States
Cedars-Sinai Medical Center

Completed

Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy

Prostate Cancer

United States
Tracon Pharmaceuticals Inc.

Terminated

Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma

Renal Cell Carcinoma

United States, Hungary, Czechia, United Kingdom
Tracon Pharmaceuticals Inc.

Completed

Trial of TRC105 and Sorafenib in Patients With HCC

Hepatocellular Carcinoma

United States
Tracon Pharmaceuticals Inc.

Completed

Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma (TAPPAS)

Advanced Angiosarcoma

United States, France, Italy, Austria, Germany, Poland, Spain, United Kingdom
Tracon Pharmaceuticals Inc.

Completed

TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma

Choriocarcinoma

United States
Amgen Research (Munich) GmbH

Completed

Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

Germany
MorphoSys AG

Completed

Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Bulgaria, Germany, Netherlands, Poland, Ukraine
Amgen Research (Munich) GmbH

Completed

Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL

Non-Hodgkin's Lymphoma, Relapsed

Germany
Tracon Pharmaceuticals Inc.

Terminated

Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)

Gestational Trophoblastic Neoplasia | Choriocarcinoma | Placental Site Trophoblastic Tumor | Epithelioid Trophoblastic Tumor

United States
Tracon Pharmaceuticals Inc.

Completed

Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated

Adult Solid Tumor

United States
Amgen Research (Munich) GmbH

Completed

Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer (MT110-101)

Solid Tumors

Germany
Amgen Research (Munich) GmbH

Completed

Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

United States, Germany, Austria, Canada, France, Italy, Netherlands
Amgen Research (Munich) GmbH

Completed

Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)

B-ALL

Germany
Amgen Research (Munich) GmbH

Completed

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

Germany
Amgen Research (Munich) GmbH

Completed

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

United States, United Kingdom, Germany, Spain, France, Italy
Amgen Research (Munich) GmbH

Completed

Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) (BLAST)

B-cell Acute Lymphoblastic Leukemia

Austria, Belgium, France, Germany, Italy, Netherlands, Poland, Romania, Russian Federation, Spain, United Kingdom
Tracon Pharmaceuticals Inc.
United States Department of Defense; Roswell Park Cancer Institute

Completed

Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer (TRC105)

Metastatic Breast Cancer

United States
Tracon Pharmaceuticals Inc.

Completed

Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer

Cancer | Neoplasm Metastasis

United States
Tracon Pharmaceuticals Inc.

No longer available

Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

Solid Tumors

United States
Micell Technologies
Cardialysis BV; ClinLogix. LLC

Unknown

Trial of MiStent Compared to Xience in Japan (DESSOLVEJ)

Coronary (Artery); Disease

Japan
Tracon Pharmaceuticals Inc.
The Cleveland Clinic; Case Comprehensive Cancer Center

Completed

A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma (105GM201)

Glioblastoma | Glioblastoma Multiforme

United States
Tracon Pharmaceuticals Inc.
University of Alabama at Birmingham

Completed

Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC

Non Small Cell Lung Cancer
Amgen

Completed

Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

China
Karen Reckamp, MD, MS
Enviro Therapeutics, Inc.

Recruiting

Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

Lung Cancer | Non Small Cell Lung Cancer

United States
Amgen

Terminated

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

United States, France, Italy, Belgium, Canada, Mexico, Germany, Korea, Republic of, United Kingdom, Taiwan, Australia, Spain, Austria, Israel, Czechia, Greece, Russian Federation, Poland, Turkey, Bulgaria, Ireland
Peptron, Inc.

Not yet recruiting

To Compare the Safety and Pharmacokinetics of PT105 With PT105R in Healthy Postmenopausal Female Volunteers

Prostate Cancer
National Cancer Institute (NCI)

Recruiting

Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

United States

Search clinical trials for: MTR105

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations